Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India.
Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(Amount in INR crores except per share data)

Particulars	Consolidated						Standalone					
	Quarter ended			Nine Months ended		Year ended	Quarter ended			Nine Months ended		Year ended
	31-Dec-23 (Unaudited)	30-Sep-23 (Unaudited)	31-Dec-22 (Unaudited)	31-Dec-23 (Unaudited)	31-Dec-22 (Unaudited)	31-Mar-23 (Audited)	31-Dec-23 (Unaudited)	30-Sep-23 (Unaudited)	31-Dec-22 (Unaudited)	31-Dec-23 (Unaudited)	31-Dec-22 (Unaudited)	31-Mar-23 (Audited)
Total income	3,718.56	3,325.22	3,200.67	10,268.35	8,734.78	12,011.13	537.83	529.69	409.33	1,536.24	1,141.82	1,583.51
Net profit/ (loss) before tax	233.46	(5.16)	173.44	301.55	329.30	535.08	53.19	56.69	41.44	162.70	128.28	182.33
Net profit/ (loss) after tax	209.22	(15.33)	159.03	213.74	292.90	475.49	53.19	59.06	34.58	165.07	121.42	173.29
Total Comprehensive Income/ (loss)	208.96	12.75	191.59	238.90	466.88	674.44	53.19	59.06	34.58	165.07	121.42	173.70
Equity Share Capital	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52
Other Equity	-	-	-	-	-	3,948.55	-	-	-	-	-	2,631.04
Earnings per share (Face value of INR 10 each)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised
Basic	3.60	(0.62)	2.80	3.08	5.11	8.54	1.07	1.19	0.70	3.32	2.44	3.48
Diluted	3.60	(0.62)	2.80	3.08	5.10	8.53	1.07	1.19	0.69	3.31	2.44	3.48

- The unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee on February 08, 2024 and approved by the Board of Directors at its meeting held on February 08, 2024.
- The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial statements is made available on the Company's website at www.asterdmhealthcare.com/investors and stock exchange website at BSE https://www.bseindia.com/ and NSE https://www.nseindia.com/.
- The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

For **Aster DM Healthcare Limited**
Sd/-
Alisha Moopen
Deputy Managing Director
DIN: 02432525

Place: Dubai
Date: February 08, 2024

CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat
Phone No. : +91-79-68138700 || **Fax** : +91-79-68138725 || **CIN** : L24230GJ1984PLC007440
Email Id : complianceofficer@concordbiotech.com || **Website** : www. concordbiotech.com
Regd. Office & Plant : 1482-86, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India
Phone No. : +91-2714-222604, 398200 || **Fax** : +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

(Rs. In lakhs except per share data)

Sl. No	Particulars	Standalone (Unaudited)			Consolidated (Unaudited)		
		Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022
1	Total Income from Operations	24,079.65	69,796.98	24,068.29	24,079.65	69,796.98	24,068.29
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,455.30	20,751.75	7,907.55	7,757.27	21,308.69	7,736.83
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(64.87)	(40.36)	17.94	(64.87)	(40.36)	17.94
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	1,28,151.88			1,28,151.88		
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations - Not Annualised)						
	1) Basic	7.13	19.84	7.56	7.41	20.37	7.40
	2) Diluted	7.13	19.84	7.56	7.41	20.37	7.40

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly / Nine Months Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com
(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules /AS Rules, whichever is applicable.
(c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 08, 2024.

For and on behalf of board of directors of Concord Biotech Limited
Ankur Vaid
Joint Managing Director & CEO - DIN : 01857225

Place : Ahmedabad
Date : Fennruary 8, 2024

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

zydus Dedicated To Life

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481
Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com
CIN : L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023

Rupees in Million

Sr. No.	Particulars	3 Months ended 31/12/2023 (Unaudited)	Preceding 3 Months ended 30/09/2023 (Unaudited)	Corresponding 3 Months ended 31/12/2022 in the previous year (Unaudited)	Year to date figures for the current period ended 31/12/2023 (Unaudited)	Year to date figures for the previous period ended 31/12/2022 (Unaudited)	Previous year ended 31/03/2023 (Audited)
1	Total income from operations	**45,052**	43,688	42,571	**140,136**	122,269	172,374
2	Net Profit for the period before exceptional items and tax	**9,255**	10,072	7,801	**32,761**	21,068	31,939
3	Net Profit for the period after exceptional items but before tax	**9,255**	10,072	7,801	**32,619**	21,039	25,897
4	Net Profit for the period from continuing operations	**7,678**	8,017	6,225	**26,574**	16,661	19,649
5	Profit/ [Loss] after tax from discontinued operations	**218**	(10)	4	**198**	(24)	(46)
6	Net Profit for the period after tax and Non-Controlling Interest	**7,896**	8,007	6,229	**26,772**	16,637	19,603
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	**8,099**	7,446	5,479	**26,476**	13,444	16,459
8	Paid-up equity share capital (Face value Re. 1/-)	**1,012**	1,012	1,012	**1,012**	1,012	1,012
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)						174,146
10	Earnings per share for continuing operations (not annualised for the quarter and nine months)						
a	Basic (Rs.)	**7.59**	7.92	6.15	**26.25**	16.39	19.35
b	Diluted (Rs.)	**7.59**	7.92	6.15	**26.25**	16.39	19.35
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)						
a	Basic (Rs.)	**7.80**	7.91	6.15	**26.45**	16.36	19.30
b	Diluted (Rs.)	**7.80**	7.91	6.15	**26.45**	16.36	19.30

Note:
[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

By Order of the Board,
For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel
Managing Director
DIN: 00131995

Date: February 9, 2024
Place: Ahmedabad

PSP Projects Limited

PSP Build to Last

CIN :L45201GJ2008PLC054868
Registered Office : PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058
Website : www.pspprojects.com

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023

(₹ in Lakhs)

Sr. No.	Particular	Consolidated		
		Quarter Ended		Nine Months Ended
		31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)
1.	Total Income from Operations	71,118.31	50,659.07	1,85,617.46
2.	Net Profit for the period (before Tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	4,204.40	4,824.99	14,468.84
3.	Net Profit for the period (after tax, Exceptional and Extraordinary Items before Share of Profit/(Loss) from Joint Venture)	3,106.66	3,532.82	10,737.75
4.	Net Profit for the period (after tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	3,108.32	3,536.01	10,745.06
5.	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	3,110.62	3,538.31	10,751.96
6.	Paid-up Equity Share Capital - Face Value ₹10/- each	3,600.00	3,600.00	3,600.00
7.	Other Equity excluding Revaluation Reserves	-	-	-
8.	Earnings Per Share of ₹ 10/-each (in ₹) (Not Annualised)			
	Basic	8.63	9.82	29.85
	Diluted	8.63	9.82	29.85

Notes:
1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09, 2024.
2. Additional information on Unaudited Standalone Financial Results are as follows: (₹ in Lakhs)

Particular	Standalone		
	Quarter Ended		Nine Months Ended
	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)
Revenue from Operations	69,661.92	49,739.28	1,81,332.80
Profit/(Loss) before tax and Exceptional item	4,397.86	4,815.39	14,636.12
Profit/(Loss) after tax and Exceptional item	3,251.85	3,529.50	10,864.77

3. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: www.pspprojects.com)

For and on behalf of Board of Directors of PSP Projects Limited
Sd/-
Prahaladbhai S. Patel
Chairman, Managing Director & CEO
DIN: 00037633

Place : Ahmedabad
Date : February 9, 2024

NCDEX

Progati ka Solid Exchange

National Commodity & Derivatives Exchange Limited

CIN : U51909MH2003PLC140116
Regd Office : Akruti Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West, Mumbai, Maharashtra 400078

Ph: 022-66406789 | **Email:** askus@ncdex.com | **Website:** www.ncdex.com

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023

(Rs. In lakhs)

Sl. No.	Particulars	Standalone			Consolidated		
		Quarter ended 31.12.2023 (Unaudited)	Quarter ended 31.12.2022 (Unaudited)	Nine months ended 31.12.2023 (Unaudited)	Quarter ended 31.12.2023 (Unaudited)	Quarter ended 31.12.2022 (Unaudited)	Nine months ended 31.12.2023 (Unaudited)
1.	Total Income from operations	1,210	1,167	4,133	3,313	3,430	10,209
2.	Net profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	(1,438)	(1,415)	(3,619)	(1,311)	(1,512)	(3,275)
3.	Net profit/ (Loss) for the period before Tax (after Exceptional and/or Extraordinary items#)	1,268	(1,415)	(323)	(1,311)	(1,548)	(3,231)
4.	Net profit/ (Loss) for the period after Tax (after Exceptional and/or Extraordinary items#)	1,488	(1,045)	321	(1,126)	(1,113)	(2,497)
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	1,521	(1,065)	357	(1,107)	(1,164)	(2,505)
6.	Equity Share Capital	5,068	5,068	5,068	5,068	5,068	5,068
7.	Reserves (excluding Revaluation Reserve) as shown in Audited Balance Sheet of the previous year	-	-	-	-	-	-
8.	Earnings Per Share (FV ₹ 10 each) (for continuing and discontinued operations)						
	1. Basic (₹): Not annualised	2.94	(2.06)	0.63	(2.15)	(2.11)	(4.69)
	2. Diluted (₹): Not annualised	2.94	(2.06)	0.63	(2.15)	(2.11)	(4.69)

Notes:

1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financials are available on our website www.ncdex.com

2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.

3 #(i) In standalone financial statements, during the quarter ended December 31,2023, the Exchange has received excess contribution of Rs.15 lakh and Rs. 590 lakh during the half year ended September 30,2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd.(NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31,2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment and the same is credited to the statement of profit and loss and shown as an Exceptional item.

(ii) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has sold 8.71% (31 lakh equity share) of its stake in its subsidiary, NCDEX e-Markets Limited (NeML), to its wholly owned subsidiary, NCCL, for a consideration of Rs. 3,000.80 lakh.The profit earned on the said stake sale of Rs. 2,691 lakh has been credited to the statement of profit and loss and shown as an exceptional item.

(iii) In case of subsidiary NCDEX e Markets Limited (NeML), NeML has incurred expenses of Rs. 36 Lakhs on newly incorporated Joint Venture during the nine months ended December 31, 2022. As the approval for commencement of business is awaited from the relevant authority, the said expenses have been shown as an exceptional item.

(iv) In case of subsidiary NCDEX e Markets Limited (NeML), during the nine months ended December 31, 2023, exceptional Income of Rs 44 lakh is on account of income booked for recovery of Preincorporation and other expenses incurred on behalf of newly incorporated JV, prior to receipt of approval from Regulatory authorities.

For and on behalf of the Board of Directors
sd/-
Arun Raste
Managing Director & Chief Executive Officer
DIN - 08561128

Place: Mumbai
Date: February 9, 2024

BERAR FINANCE LIMITED

BERAR 1990 Partnership for Prosperity

CIN:U65929MH1990PLC057829
Regd.Office: AVINISHA TOWER,MEHADIA CHOWK, DHANTOLI, NAGPUR - 440 012. Ph no.0712-6663999
Website: www.berarfinance.com
E-mail: investor.relations@berarfinance.com

Extract of Financial Results for the quarter ended December 31, 2023
[Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)]

(₹ in Lakhs, except per equity share data and Debt Equity Ratio)

Sr. No.	PARTICULARS	Quarter ended Dec. 31, 2023 UNAUDITED	Quarter ended Dec. 31, 2022 UNAUDITED	Year ended March 31,2023 AUDITED
1	Total Income from Operations	6662.90	6259.69	21788.93
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
4	Net Profit /(Loss)for the period after tax (after Exceptional and/or Extraordinary items#)	517.58	892.62	1708.12
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	522.11	897.90	1709.27
6	Paid -up Equity Share Capital	1233.68	1233.68	1233.68
7	Reserves (excluding Revaluation Reserve)	11895.60	10345.60	11895.60
8	Securities Premium Account	14123.94	14123.94	14123.94
9	Net worth (Including Retained earnings and ESOP)	29113.77	27579.63	27523.60
10	Paid up Debt Capital/ Outstanding Debt	92679.81	85014.88	83190.22
11	Outstanding Redeemable Preference Shares	NA	NA	NA
12	Debt Equity Ratio	3.18	3.08	3.02
13	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)*			
	a) Basic	4.20	7.24	13.85
	b) Diluted	4.18	7.24	13.79
14	Capital Redemption Reserve	NA	NA	NA
15	Debenture Redemption Reserve	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA

 # Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind AS Rules.

*** Not annualised for quarter ended December 31, 2023 and December 31, 2022.**

Notes :

a) The above Results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on February 09, 2024.
b) The above is an extract of the detailed format of financial results filed with the BSE Limited ("Stock Exchange") under Regulation 52 of the SEBI Listing Regulations. The full format of the financial results is available on the website of the Stock Exchange i.e www.bseindia.com and on the website of the Company i.e www.berarfinance.com
c) For the other line items referred in regulation 52 (4) of the SEBI Listing Regulations, pertinent disclosures have been made to BSE Limited and can be accessed on www.bseindia.com. and on the website of the Company i.e www.berarfinance.com
d) This Extract of Financial Results has been prepared in accordance with the requirement of Regulation 52 of the SEBI Listing Regulations read with Operational Circular bearing reference no. SEBI /HO /DDHS /DDHS_Div1 /P /CIR/2022/0000000103 dated July 29, 2022 as amended ("Circular").

For and on behalf of Board of Directors of Berar Finance Limited
Sd/-
(Sandeep Jawanjal)
Managing Director
DIN: 01490054

Place: Nagpur
Date: February 09, 2024

2027ರ ಅಂತ್ಯಕ್ಕೆ ಉಪನಗರ ರೈಲು ಸಂಚಾರ

ಮೊದಲನೇ ಪುಟದಿಂದ... **ಯೋಜನೆಗೆ ಶೇ.60 ಸಾಲ:** ಬೆಂಗಳೂರಿನ ಜನರ ಜೀವನ ಸುಗಮಗೊಳಿಸುವುದು ಸಬರ್ಬನ್ ರೈಲು ಯೋಜನೆ ಉದ್ದೇಶವಾಗಿದೆ. ಒಟ್ಟು 15,767 ಕೋಟಿ ರೂ. ವೆಚ್ಚದ ಈ ಯೋಜನೆಯು 58 ನಿಲ್ದಾಣಗಳನ್ನು ಹೊಂದಿರಲಿದ್ದು, ಒಟ್ಟು 4 ಕಾರಿಡಾರ್‌ಗಳಲ್ಲಿ 148 ಕಿ.ಮೀ. ಇರಲಿದೆ. ಈ ಯೋಜನೆಗೆ ರೈಲ್ವೆ ಸಚಿವಾಲಯ ಮತ್ತು ರಾಜ್ಯ ಸರ್ಕಾರಗಳು ತಲಾ ಶೇ.20 ಹೂಡಿಕೆ ಮಾಡಲಿದ್ದು, ಬಾಹ್ಯ ಸಾಲದ ರೂಪದಲ್ಲಿ ಶೇ.60 ಸಂಪನ್ಮೂಲ ಕ್ರೋಢೀಕರಣ ಮಾಡಲಾಗುವುದು ಎಂದರು. ಜರ್ಮನಿ ಕಾನ್ಸುಲ್ ಜನರಲ್ ಅಕಿಂ ಬರ್ಕಾರ್ಟ್, ನಗರಾಭಿವೃದ್ಧಿ ಇಲಾಖೆ ಹೆಚ್ಚುವರಿ ಮುಖ್ಯ ಕಾರ್ಯದರ್ಶಿ ರಾಕೇಶ್ ಸಿಂಗ್, ಕೆಎಫ್‌ಡಬ್ಲ್ಯುದ ಸ್ವಾತಿ ಖನ್ನಾ ಮತ್ತು ಕಾಂಚಿ ಅರೋರಾ ಇದ್ದರು.

ನಾಳೆ ನೇರಳೆ ಮಾರ್ಗದ ಮೆಟ್ರೋ ಸಂಚಾರ ವ್ಯತ್ಯಯ

ಬೆಂಗಳೂರು: ನೇರಳೆ ಮಾರ್ಗದ ಟ್ರಿನಿಟಿ ಮತ್ತು ಎಂ.ಜಿ. ರಸ್ತೆ ನಿಲ್ದಾಣಗಳ ನಡುವೆ ನಿರ್ವಹಣೆ ಕಾಮಗಾರಿ ಹಿನ್ನೆಲೆ ಭಾನುವಾರ (ಫೆ.11) ಬೆಳಗ್ಗೆ 7 ಗಂಟೆಯಿಂದ 9 ಗಂಟೆವರೆಗೆ ಮೆಟ್ರೋ ಸೇವೆ ಇರುವುದಿಲ್ಲ. ಆದರೆ, ಈ ಅವಧಿಯಲ್ಲಿ ರೈಲುಗಳು ಎಂ.ಜಿ. ರಸ್ತೆ ಮತ್ತು ಚಲ್ಲಘಟ್ಟ ಹಾಗೂ ಇಂದಿರಾನಗರ ಮತ್ತು ವೈಟ್‌ಫೀಲ್ಡ್ ನಡುವೆ ಸಂಚರಿಸಲಿವೆ. ಹಸಿರು ಮಾರ್ಗದಲ್ಲಿ ಬದಲಾವಣೆ ಇರುವುದಿಲ್ಲ.

ವೆಚ್ಚಕ್ಕೆ ಸರ್ಕಾರ ಎಚ್ಚರಿಕೆ ಹೆಜ್ಜೆ

ಮೊದಲನೇ ಪುಟದಿಂದ... ಆದ್ದರಿಂದ ಆಡಳಿತ ಇಲಾಖೆಗಳು ಹಣ ಬಿಡುಗಡೆ ಮಾಡುವಾಗ ಅನುಷ್ಠಾನಗೊಳಿಸುವ ಏಜೆನ್ಸಿಗಳ ಹೆಸರಿನ ಖಾತೆಗಳಲ್ಲಿರುವ ಮೊತ್ತ ಪರಿಶೀಲಿಸಿ ಬಿಡುಗಡೆಗೊಳಿಸುವಂತೆ ತಿಳಿಸಲಾಗಿದೆ. ಕೆಲ ಇಲಾಖೆಗಳು ಕೇಂದ್ರ ಸರ್ಕಾರದ ಪಾಲು ನಿರೀಕ್ಷಿಸಿ ಹಣ ಬಿಡುಗಡೆ ಮಾಡುತ್ತಿರುವುದು ಆರ್ಥಿಕ ಇಲಾಖೆ ಗಮನಕ್ಕೆ ಬಂದಿದೆ. ಇಂತಹ ಪ್ರಕರಣಗಳು ಇಲಾಖೆ ಗಮನಕ್ಕೆ ಬಂದಲ್ಲಿ ಈ ಯೋಜನೆಯಡಿ ಮುಂದಿನ ಬಿಡುಗಡೆ ನಿಲ್ಲಿಸಲಾಗುವುದು ಎಂದು ಎಚ್ಚರಿಸಲಾಗಿದೆ.